Diadema Partners’s CytomX Therapeutics CTMX Stock Holding History

Diadema Partners’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Buy	+316,000	New	+$1.6M	0.25%	73

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Diadema Partners's CTMX Position: Q4 2025 in Review

Diadema Partners sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 185,286 shares — an estimated $591K sold.

Diadema Partners first reported a position in CTMX in Q3 2025 and held it in 1 quarter. The position peaked at $591K in Q3 2025. 121 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

Diadema Partners reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 185,286 CytomX Therapeutics shares in Q4 2025, an estimated $591K.
Diadema Partners first reported a position in CytomX Therapeutics in Q3 2025 and held it in 1 quarter.
Diadema Partners's CytomX Therapeutics position peaked at $591K in Q3 2025.
121 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.